---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-003807"
form_type: "8-K"
ticker: "GANX"
cik: "0001819411"
company_name: "Gain Therapeutics, Inc."
filed_at: "2025-03-27T23:59:59+00:00"
generated_at: "2026-05-24T04:13:05.425069+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Gain Therapeutics reports FY2024 net loss $20.4M; Phase 1b dosing initiated for GT-02287

## Summary
- Net loss of $20.4M ($0.89 EPS) vs $22.3M ($1.71 EPS) in FY2023; revenue not reported.
- Cash and securities $10.4M at Dec 31, 2024, down from $16.8M a year earlier.
- First patient dosed in Phase 1b trial of GT-02287 for Parkinson's disease; first analysis expected Q2 2025.
- Gene Mack appointed President and CEO effective Jan 6, 2025; pre-IND engagement with FDA started.
- R&D expenses fell to $10.8M and G&A to $9.6M vs $11.5M and $10.8M in FY2023.

## SEC filing metadata
- accession: 0001558370-25-003807
- form_type: 8-K
- ticker: GANX
- cik: 0001819411
- company_name: Gain Therapeutics, Inc.
- filed_at: 2025-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819411/000155837025003807/0001558370-25-003807-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819411/000155837025003807/ganx-20250327x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-003807
- JSON: https://secwatch.observer/filing/0001558370-25-003807.json
- Plain text: https://secwatch.observer/filing/0001558370-25-003807.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.